Dianthus Therapeutics DNTH Discovery Expenses — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's discovery expenses — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's discovery expenses — research and development expense?
- Dianthus Therapeutics (DNTH) reported discovery expenses — research and development expense of $1.36M in Q1 2026.
- How has Dianthus Therapeutics's discovery expenses — research and development expense changed year-over-year?
- Dianthus Therapeutics's discovery expenses — research and development expense increased by 51.4% year-over-year, from $900K to $1.36M.
- What does discovery expenses — research and development expense mean?
- This metric represents the aggregate costs incurred by the company specifically for early-stage research and discovery activities within its drug development pipeline. It captures the financial resources dedicated to identifying and validating novel therapeutic candidates before they advance into formal clinical trials. Monitoring this expense provides insight into the company's commitment to innovation and the sustainability of its long-term drug development engine.